Accéder au contenu
Merck

Assessment of enhanced influenza vaccination finds that FluAd conveys an advantage in mice and older adults.

Clinical & translational immunology (2020-02-07)
Niloufar Kavian, Asmaa Hachim, Athena Py Li, Carolyn A Cohen, Alex Wh Chin, Leo Lm Poon, Vicky J Fang, Nancy Hl Leung, Benjamin J Cowling, Sophie A Valkenburg
RÉSUMÉ

Enhanced inactivated influenza vaccines (eIIV) aim to increase immunogenicity and protection compared with the widely used standard IIV (S-IIV). We tested four vaccines in parallel, FluZone high dose, FluBlok and FluAd versus S-IIV in a randomised controlled trial of older adults and in a mouse infection model to assess immunogenicity, protection from lethal challenge and mechanisms of action. In older adults, FluAd vaccination stimulated a superior antibody profile, including H3-HA antibodies that were elevated for up to 1 year after vaccination, higher avidity H3HA IgG and larger HA stem IgG responses. In a mouse model, FluAd also elicited an earlier and larger induction of HA stem antibodies with increased germinal centre responses and upregulation and long-term expression of B-cell switch transcription factors. Long-term cross-reactive memory responses were sustained by FluAd following lethal heterosubtypic influenza challenge, with reduced lung damage and viral loads, coinciding with increased T- and B-cell recall. Advantages were also noted for the high-dose FluZone vaccine in both humans and mice. The early, broadly reactive and long-lived antibody response of FluAd indicates a potential advantage of this vaccine, particularly in years when there is a mismatch between the vaccine strain and the circulating strain of influenza viruses.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Mouse IgG2b ELISA Kit
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
RéférenceRéf. du fournisseurConditionnementDisponibilitéPrix
EN300-1072808-100MG100 mg
Expédition sous 14 jour(s) - par un Aldrich Partner.
468,80 €
EN300-1072808-250MG250 mg
Expédition sous 14 jour(s) - par un Aldrich Partner.
648,20 €
EN300-1072808-500MG500 mg
Expédition sous 14 jour(s) - par un Aldrich Partner.
995,30 €
EN300-1072808-1G1 g
Expédition sous 14 jour(s) - par un Aldrich Partner.
1 264,40 €
EN300-1072808-2.5G2.5 g
Expédition sous 14 jour(s) - par un Aldrich Partner.
2 434,40 €
EN300-1072808-5G5 g
Expédition sous 14 jour(s) - par un Aldrich Partner.
3 582,30 €
EN300-1072808-10G10 g
Expédition sous 14 jour(s) - par un Aldrich Partner.
5 290,50 €

Pour commander des produits, veuillez contacter contact votre distributeur local.